SCHEMBL24967786

SCHEMBL24967786

Cc1nn2cc(C(C)(C)C)cnc2c1O

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.35
NPC1 O15118 4/20 0.35
KMT2A Q03164 3/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
STAT3 P40763 1/20 0.35
STAT1 P42224 1/20 0.35
CASP3 P42574 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
MAPT P10636 5/20 0.35
SMN1; SMN2 Q16637 5/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
LMNA P02545 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21752735 0.76 TDP1 (0.43) RAB9ANPC1KMT2AMEN1ALDH1A1
SCHEMBL25097592 0.70 KDR (0.32)
SCHEMBL19678268 0.67 NPC1 (0.35) RAB9ANPC1KMT2AMEN1ALDH1A1
SCHEMBL29297307 0.67 FLT1 (0.30)
SCHEMBL16643961 0.66 MAPT (0.40) RAB9ANPC1KMT2AMEN1ALDH1A1
SCHEMBL19678264 0.66 SMN1; SMN2 (0.53) RAB9ANPC1KMT2AMEN1ALDH1A1
SCHEMBL25818110 0.65 ALDH1A1 (0.41) RAB9ANPC1KMT2AALDH1A1MAPT
SCHEMBL29297630 0.64
SCHEMBL18806118 0.63 NPC1 (0.39) RAB9ANPC1ALDH1A1MAPTSMN1; SMN2
SCHEMBL25097590 0.62 KDM4E (0.51) ALDH1A1SMN1; SMN2L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230022157-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2023-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230022157-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS CFD, CFH, TFPI RAB9A 1876/4885NPC1 477/4885KMT2A 4738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.